Virtual Reality for Generalized Anxiety Disorders (VR-GAD)
A Randomized Control Trial of the Use of Virtual Reality as an Adjunct in the Treatment for Generalized Anxiety Disorders
The goal of this clinical trial is to apply Virtual Reality as an adjunct treatment for Generalized Anxiety Disorder. The main question it aims to answer are:
- Determination of the efficacy of VR modules as an adjunct therapy in improving GAD-7 scores
- Assessment of the acceptability of VR modules as an adjunct therapy to the standard of care
Participants will randomized into two arms:
- Control Arm: Standard of Care only
- Intervention Arm: Standard of Care + VR Modules
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Dr. Mohd Aizuddin Abdul Rahman
- Phone Number: +60126877225
- Email: drmohdaizu@gmail.com
Study Locations
-
-
Johor
-
Johor Bahru, Johor, Malaysia, 80100
- Hospital Sultanah Aminah
-
Johor Bahru, Johor, Malaysia, 81200
- Hospital Permai
-
-
Kedah
-
Alor Setar, Kedah, Malaysia, 05460
- Hospital Sultanah Bahiyah
-
Kulim, Kedah, Malaysia, 09090
- Hospital Kulim
-
-
Terengganu
-
Kuala Terengganu, Terengganu, Malaysia, 20400
- Hospital Sultanah Nur Zahirah
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age between 18-59
- The primary diagnosis is a generalized anxiety disorder
- Agree to participate and consented as per study protocol.
- There is no change in the standard of care within the past two months prior to enrollment into the study. If a patient is on any psychotherapy, then there is no change in the type of current psychotherapy intervention.
- GAD- 7 more than or equal to 5.
- Able to come for the session as per scheduled.
Exclusion Criteria:
- Documented or known case of permanent hearing/visual impairment e.g., vestibular abnormalities that represent significant contraindications for the use of VR or visual impairment e.g., cataract.
Documented Disorder as listed:
- A. Psychosis
- B. Psychosis disorder - previous case, known case of
- C. Claustrophobia
- D. Substance use
- E. Personality disorder
- F. Visual impairment that might hinder usage of virtual reality equipment
- G. Intellectual disabilities
- H. All types of seizures including febrile seizure
- The patient is under more than 1 center during follow up (e.g., patient is also receiving treatment from a private hospital for GAD).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Control
Standard Of Care only
|
|
|
Other: Intervention
Standard Of Care + VR Modules
|
Virtual Reality as adjunct treatment
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To determine the efficacy of VR modules as an adjunct therapy in improving GAD-7 scores among patients with generalized anxiety disorders.
Time Frame: Week 0 - Week 4
|
Patient will be access with GAD-7 questionnaire repeatedly at different time interval (3 Times - Week 0, Week 2, Week 4) .
|
Week 0 - Week 4
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To assess the acceptability of VR modules as an adjunct therapy to the standard of care among patients with generalized anxiety disorders.
Time Frame: Week 0 - Week 4
|
Patient will assess with standard questionnaire on acceptability of VR technology (3 Times - Week 0, Week 2, Week 4).
|
Week 0 - Week 4
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NMRR-22-00741-C75
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.